205 related articles for article (PubMed ID: 2924317)
1. Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.
Colcher D; Milenic D; Roselli M; Raubitschek A; Yarranton G; King D; Adair J; Whittle N; Bodmer M; Schlom J
Cancer Res; 1989 Apr; 49(7):1738-45. PubMed ID: 2924317
[TBL] [Abstract][Full Text] [Related]
2. Generation and characterization of a recombinant/chimeric B72.3 (human gamma 1).
Hutzell P; Kashmiri S; Colcher D; Primus FJ; Hand PH; Roselli M; Finch M; Yarranton G; Bodmer M; Whittle N
Cancer Res; 1991 Jan; 51(1):181-9. PubMed ID: 1988082
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
4. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49.
Milenic DE; Yokota T; Filpula DR; Finkelman MA; Dodd SW; Wood JF; Whitlow M; Snoy P; Schlom J
Cancer Res; 1991 Dec; 51(23 Pt 1):6363-71. PubMed ID: 1933899
[TBL] [Abstract][Full Text] [Related]
5. Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer.
Meredith RF; Khazaeli MB; Grizzle WE; Orr RA; Plott G; Urist MM; Liu T; Russell CD; Wheeler RH; Schlom J
Hum Antibodies Hybridomas; 1993 Oct; 4(4):190-7. PubMed ID: 8257773
[TBL] [Abstract][Full Text] [Related]
6. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies.
Colcher D; Minelli MF; Roselli M; Muraro R; Simpson-Milenic D; Schlom J
Cancer Res; 1988 Aug; 48(16):4597-603. PubMed ID: 3396011
[TBL] [Abstract][Full Text] [Related]
7. Enhanced tumor binding using immunohistochemical analyses by second generation anti-tumor-associated glycoprotein 72 monoclonal antibodies versus monoclonal antibody B72.3 in human tissue.
Molinolo A; Simpson JF; Thor A; Schlom J
Cancer Res; 1990 Feb; 50(4):1291-8. PubMed ID: 2297774
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans.
Khazaeli MB; Saleh MN; Liu TP; Meredith RF; Wheeler RH; Baker TS; King D; Secher D; Allen L; Rogers K
Cancer Res; 1991 Oct; 51(20):5461-6. PubMed ID: 1913665
[TBL] [Abstract][Full Text] [Related]
9. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
[TBL] [Abstract][Full Text] [Related]
10. In vivo fate of monoclonal antibody B72.3 in patients with colorectal cancer.
Colcher D; Milenic DE; Ferroni P; Carrasquillo JA; Reynolds JC; Roselli M; Larson SM; Schlom J
J Nucl Med; 1990 Jul; 31(7):1133-42. PubMed ID: 2362192
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a mouse/human chimeric monoclonal antibody (17-1A) to a colon cancer tumor-associated antigen.
Shaw DR; Khazaeli MB; Sun LK; Ghrayeb J; Daddona PE; McKinney S; LoBuglio AF
J Immunol; 1987 Jun; 138(12):4534-8. PubMed ID: 3584980
[TBL] [Abstract][Full Text] [Related]
12. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota T; Milenic DE; Whitlow M; Schlom J
Cancer Res; 1992 Jun; 52(12):3402-8. PubMed ID: 1596900
[TBL] [Abstract][Full Text] [Related]
13. Phenotypic characterization of lung cancers in fine needle aspiration biopsies using monoclonal antibody B72.3.
Johnston WW; Szpak CA; Thor A; Schlom J
Cancer Res; 1986 Dec; 46(12 Pt 1):6462-70. PubMed ID: 3022920
[TBL] [Abstract][Full Text] [Related]
14. Chimeric B72.3 mouse/human (IgG1) antibody directs the lysis of tumor cells by lymphokine-activated killer cells.
Primus FJ; Pendurthi TK; Hutzell P; Kashmiri S; Slavin DC; Callahan R; Schlom J
Cancer Immunol Immunother; 1990; 31(6):349-57. PubMed ID: 2386980
[TBL] [Abstract][Full Text] [Related]
15. Applications of monoclonal antibodies in clinical cytology as exemplified by studies with monoclonal antibody B72.3. The George N. Papanicolaou award lecture.
Johnston WW
Acta Cytol; 1987; 31(5):537-56. PubMed ID: 3314301
[TBL] [Abstract][Full Text] [Related]
16. Human biodistribution of 111In-labeled B72.3 monoclonal antibody.
Harwood SJ; Carroll RG; Webster WB; Zangara LM; Laven DL; Morrissey MA; Sinni BJ
Cancer Res; 1990 Feb; 50(3 Suppl):932s-936s. PubMed ID: 2297744
[TBL] [Abstract][Full Text] [Related]
17. Biologic properties of a CH2 domain-deleted recombinant immunoglobulin.
Slavin-Chiorini DC; Horan Hand PH; Kashmiri SV; Calvo B; Zaremba S; Schlom J
Int J Cancer; 1993 Jan; 53(1):97-103. PubMed ID: 8416208
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.
Muraro R; Kuroki M; Wunderlich D; Poole DJ; Colcher D; Thor A; Greiner JW; Simpson JF; Molinolo A; Noguchi P
Cancer Res; 1988 Aug; 48(16):4588-96. PubMed ID: 3396010
[TBL] [Abstract][Full Text] [Related]
19. Autoradiographic evaluation of radiolabeled monoclonal antibody B72.3 distribution in tumor and lymph nodes of adenocarcinoma patients.
Roselli M; Hitchcock CL; Molinolo A; Milenic DE; Colcher D; Martin EW; Hinkle GH; Schlom J
Anticancer Res; 1995; 15(3):975-84. PubMed ID: 7645989
[TBL] [Abstract][Full Text] [Related]
20. The use of monoclonal antibody B72.3 in the management of gynecologic malignancies.
Simpson J; Schlom J
Yale J Biol Med; 1988; 61(4):351-66. PubMed ID: 3055701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
